Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Immunotherapy against murine leukemia

S de Vos¹, D B Kohn, S K Cho

¹Division of Hematology/Oncology, Cedars-Sinai-Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA.

|April 7, 1998

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The treatment of adenosine deaminase deficiency.

Immunology today·2014

Same author

Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector.

Gene therapy·2010

Same author

Lentiviral vectors with amplified beta cell-specific gene expression.

Gene therapy·2009

Same author

Tissue-specific restriction of cyclophilin A-independent HIV-1- and SIV-derived lentiviral vectors.

Gene therapy·2008

Same author

Gene therapy for childhood immunological diseases.

Bone marrow transplantation·2007

Same author

The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors.

Gene therapy·2007

Same journal

Linperlisib enhances MUC1-Tn CAR T cell efficacy by inhibiting EGR1/DUSP2 axis to prevent CAR T cell exhaustion.

Leukemia·2026

Same journal

CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

Leukemia·2026

Same journal

Single-cell architecture of purinergic signaling in human cord blood hematopoietic stem and progenitor cells.

Leukemia·2026

Same journal

Feasibility and safety of rapid glofitamab ramp-up.

Leukemia·2026

Same journal

Single-cell DNA methylation analysis uncovers epigenetic pathways in the transformation of MDS to AML.

Leukemia·2026

Same journal

PD-L2 is associated with lineage-related transcriptional programs distinct from PD-L1 in primary mediastinal large B-cell lymphoma.

Leukemia·2026

See all related articles

This study shows interleukin-7 (IL-7) and interleukin-2 (IL-2) enhance anti-leukemia immunotherapy in mice. These cytokines improve survival rates against myeloid leukemia, unlike granulocyte-macrophage colony-stimulating factor (GM-CSF).

Area of Science:

Immunology
Oncology
Biotechnology

Background:

Leukemia immunotherapy relies on targeting leukemia-specific antigens.
A murine myeloid leukemia model (WEHI3) was used to test novel immunization strategies.

Purpose of the Study:

To evaluate the efficacy of cytokine-engineered vaccines in a murine leukemia model.
To identify effective cytokines for enhancing anti-leukemia immune responses.

Main Methods:

Developed a syngeneic mouse model using WEHI3 leukemia.
Vaccinated mice with irradiated WEHI3 cells engineered to produce IL-7, IL-2, or GM-CSF.
Assessed survival rates after challenge with parental WEHI3 cells.

Main Results:

Related Experiment Videos

IL-7-producing WEHI3 vaccination resulted in 40% long-term survival.

Combination of WEHI3 cells with IL-2-producing fibroblasts yielded 60% survival.

GM-CSF-producing WEHI3 vaccination showed only 20% survival; IL-2/IL-7 combination offered no additive benefit.

Immunization against pre-established leukemia burden was ineffective.

Conclusions:

Interleukin-7 (IL-7) and Interleukin-2 (IL-2) are effective cytokines for enhancing anti-leukemia vaccination.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) demonstrated marginal activity.
Further research is needed to optimize immunization strategies for established leukemia.